Frequency of the three most common polymorphisms in the MDR1 gene in Slovak population

Neoplasma

Volumn 56, Issue 2, 2009, Pages 101-107

  Krivulcik, T ^a   Sedlak, J ^a   Bartosova, Z ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

MDR1 gene; MDR1 haplotypes; P glycoprotein; Polymorphisms; Slovak population

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOID LE; ARTICLE; CANCER PATIENT; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE 1 GENE; NORMAL HUMAN; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; SLOVAKIA; TREATMENT OUTCOME; GENETICS;

GENOTYPE; HAPLOTYPES; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 65649099373     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_02_101     Document Type: Article

References (44)

1. Thiebaut F, Tsuruo T, Hamada H et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987; 84: 7735-7738. doi:10.1073/pnas.84.21.7735
2. Cordon-Cardo C, O'BRIEN JP, BOCCIA J et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38: 1277-1287. (Pubitemid 20266126)
3. Marzolini C, Paus E, Buclin T et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33. doi:10.1016/j. clpt.2003.09.012 (Pubitemid 38130115)
4. Kerb R, AYNACIOGLU AS, BROCKMÖLLER J et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001; 1: 204-210.
5. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002; 25(11): 1391-1400. doi:10.1248/bpb.25.1391
6. LEONARD GD, FOJO T, BATES SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411-424. doi:10.1634/theoncologist.8-5-411 PMid:14530494 (Pubitemid 37238869)
7. CHEN CJ, CLARK D, UEDA K et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990; 265: 506-514. (Pubitemid 20032373)
8. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478. doi:10.1073/ pnas.050585397 (Pubitemid 30183327)
9. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174. doi:10.1067/mcp.2001.114164 (Pubitemid 32225417)
10. Morita Y, Sakaeda T, Horinouchi M et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 2003; 20: 552-556. doi:10.1023/A:1023282312757 PMid:12739761 (Pubitemid 36438897)
11. KIM RB, LEAKE BF, CHOO EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199. doi:10.1067/mcp.2001.117412 (Pubitemid 32777772)
12. Drescher S, Schaeffeler E, Hitzl M et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526-534. doi:10.1046/j.1365-2125.2002.01591.x PMid:11994059 PMCid:1874364 (Pubitemid 34527155)
13. Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6: 163-168. doi:10.1517/14622416.6.2.163 PMid:15882134 (Pubitemid 40613182)
14. Hauser Ia, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511. doi:10.1681/ ASN.2004100882 PMid:15772250 (Pubitemid 41716536)
15. Anglicheau D, Thervet E, Etienne I et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433. doi:10.1016/j.clpt.2004.01.009 (Pubitemid 38534563)
16. Pauli-Magnus C, KROETZ DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904-913. doi:10.1023/ B:PHAM.0000029276.21063.0b PMid:15212152 (Pubitemid 38870137)
17. Meissner K, Jedlitschky G, MEYER et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14: 381-385. doi:10.1097/00008571- 200406000-00007 PMid:15247630 (Pubitemid 38813692)
18. VAN DEN HEUVEL-EIBRINK MM, WIEMER EA, DE BOEVERE MJ et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001; 97: 3605-3611. doi:10.1182/blood.V97.11.3605 PMid:11369657
19. KIM DH, PARK JY, SOHN SK et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 2006; 118: 2195-2201. doi:10.1002/ijc.21666
20. Gerloff T, Schaefer M, Johne A et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610-616. doi:10.1046/j.1365-2125.2002.01691.x PMid:12492608 PMCid:1874502 (Pubitemid 36002588)
21. Horinouchi M, Sakaeda T, Nakamura T et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19: 1581-1585. doi:10.1023/A: 1020433422259 PMid:12425480 (Pubitemid 35266567)
22. Johne A, Köpke K, Gerloff T et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584-594. doi:10.1067/ mcp.2002.129196 (Pubitemid 36237730)
23. Chowbay B, Cumaraswamy S, CHEUNG YB et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89-95. doi:10.1097/00008571-200302000-00005 PMid:12563178 (Pubitemid 36259588)
24. TAN EK, CHAN DK, NG PW et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 2005; 62: 460-464. doi:10.1001/archneur.62.3.460 PMid:15767512 (Pubitemid 40349484)
25. GWEE PC, TANG K, CHUA JM et al. Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. Clin Chem 2003; 49: 672-676. doi:10.1373/49.4.672 PMid:12651828
26. GAIKOVITCH EA, CASCORBI I, MROZIKIEWICZ PM et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59: 303-312. doi:10.1007/s00228-003-0606-2 PMid:12879168
27. SALAMA NN, YANG Z, BUI T et al. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 2006; 95: 2293-2308. doi:10.1002/jps.20717 PMid:16883550
28. Jamroziak K, Balcerczak E, Młynarski W et al. Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol 2002; 54: 495-500. (Pubitemid 35214975)
29. GOREVA OB, GRISHANOVA AY, MUKHIN OV et al. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med 2003; 136: 183-185.
30. Schaeffeler E, Eichelbaum M, Brinkmann U et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358: 383-384. doi:10.1016/ S0140-6736(01)05579-5589 (Pubitemid 32739101)
31. Zhao H, Zhang S, MERIKANGAS KR et al. Transmission/disequilibrium tests using multiple tightly linked markers. Am J Hum Genet 2000; 6736-6946 (Pubitemid 30740144)
32. ALLABI AC, HORSMANS Y, ISSAOUI B et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 2005; 61: 97-102. doi:10.1007/ s00228-004-0879-880 PMid:15692830
33. Goto M, Masuda S, Saito H et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451-457. doi:10.1097/00008571-200208000-00005 PMid:12172213 (Pubitemid 34913527)
34. Tang K, NGOI SM, GWEE PC et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437-450. doi:10.1097/0000857 1-200208000-200300004 PMid:12172212 (Pubitemid 34913526)
35. KROETZ DL, PAULI-MAGNUS C, HODGES et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13: 481-494. doi:10.1097/00008571-200308 000-00006 PMid:12893986
36. Illmer T, SCHULER US, THIEDE C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62(17): 4955-4962. (Pubitemid 34984419)
37. MICKLEY LA, LEE JS, WENG Z et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-1756.
38. BERNAL ML, SINUES B, FANLO A et al. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit 2003; 25: 107-111. doi:10.1097/00007691-200302000-00016 PMid:12548153
39. AMEYAW MM, REGATEIRO F, LI T et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221. doi:10.1097/00008571-200104000-00005 PMid:11337937
40. Furuno T, LANDI MT, CERONI M et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12: 529-534. doi:10.1097/00008571-200210000- 00004 PMid:12360103 (Pubitemid 35177082)
41. Kurzawski M, Pawlik A, Górnik W et al. Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 2006; 58: 35-40.
42. Pechandová K, Buzková H, Slanar O et al. Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha) 2006; 52: 184-189. (Pubitemid 46020161)
43. Sakaeda T, Nakamura T, Horinouchi M et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400-1404. doi:10.1023/A:1012244520615 PMid:11697464 (Pubitemid 32977244)
44. Li D, ZHANG GL, LOU YQ et al. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 2007; 32: 89-95. doi:10.1111/j.1365-2710.2007.00791.x PMid:17286792 (Pubitemid 46213944)